Long-Term Safety in Atrial Fibrillation Patients
The purpose of this study is to provide safety and tolerability data for AZD0837 during long-term treatment (5 years) in patients with non-valvular atrial fibrillation (AF) and one or more additional risk factors for stroke and systemic embolic events (moderate to high risk patients)...
Brief Summary
Official Title: “Long-Term Treatment With the Oral Direct Thrombin Inhibitor AZD0837, Compared to Vitamin-K Antagonists, as Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation and One or More Risk Factors for Stroke and Systemic Embolic Events. A 5-Year Follow-up Study”
The purpose of this study is to provide safety and tolerability data for AZD0837 during long-term treatment (5 years) in patients with non-valvular atrial fibrillation (AF) and one or more additional risk factors for stroke and systemic embolic events (moderate to high risk patients).
- Study Type: Interventional
- Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Intervention(s) in this Clinical Trial
- Drug: AZD0837
- Drug: Vitamin-K Antagonists (warfarin)
Arms, Groups and Cohorts in this Clinical Trial
- Experimental: 1
- Active Comparator: 2
Outcome Measures for this Clinical Trial
Primary Measures
- To evaluate safety and tolerability of long-term treatment with AZD0837 compared to Vitamin-K Antagonist (VKA) in Atrial Fibrillation patients with a moderate to high risk of stroke and systemic embolic events.
- Safety Issue?: Yes
Secondary Measures
- To evaluate the PK of AZD0837 and metabolites; To evaluate the effect of AZD0837 on PD markers and coagulation assays in Atrial Fibrillation patients with a moderate to high risk of stroke and systemic embolic events.
- Safety Issue?: No
Criteria for Participation in this Clinical Trial
Inclusion Criteria:
- Patients with paroxysmal, persistent or permanent Non Valvular Atrial Fibrillation with one or more additional risk factors for stroke and systemic embolic event
- completing treatment with study drug in D1250C00008.
Exclusion Criteria:
- Atrial Fibrillation secondary to reversible disorders, eg hyperthyroidism
- Presence of a valvular heart disease, mechanical heart valves, active endocarditis, left ventricular aneurysm or thrombus, atrial myxoma or any condition other than
- Atrial Fibrillation requiring chronic anticoagulation treatment
- Myocardial infarction, heart surgery or percutaneous coronary intervention (PCI) within the previous three months prior to inclusion; Stroke and/or systemic embolism within the previous 30 days prior to inclusion
- Conditions associated with increased risk of major bleeding.
Gender Eligibility for this Clinical Trial: Both
Minimum Age for this Clinical Trial: 18 Years
Maximum Age for this Clinical Trial: N/A
Are Healthy Volunteers Accepted for this Clinical Trial?: No
Clinical Trial Investigator Information
Lead Investigator: AstraZeneca Industry
Overall Clinical Trial Officials and Contacts
Lars Hvilstedt Rasmussen, MD, PhD, FESC Principal Investigator Head of Cardiology at Heart Centre Aalborg Aarhus University Hospital DK 9100 Aalborg Denmark
Additional Information
Information obtained from ClinicalTrials.gov on February 12, 2012
Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00645853
Study ID Number: D1250C00042
ClinicalTrials.gov Identifier: NCT00645853
Health Authority: Denmark: Danish Medicines Agency
Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.
The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00645853
